We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 108.00 | 0.90% | 12,170.00 | 12,172.00 | 12,174.00 | 12,266.00 | 12,054.00 | 12,194.00 | 871,104 | 16:35:22 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.69 | 188.69B |
From May 2019 to May 2024
By Sabela Ojea
AstraZeneca PLC (AZN.LN) said Monday that its supplemental new drug application for Lynparza has been accepted and granted priority review in the U.S. by the Food and Drug Administration for patients with metastatic castration-resistant prostate cancer.
The pharmaceutical company said that the Prescription Drug User Fee Act date is set for the second quarter of 2020.
The London-listed company said that Lynparza is also aimed at patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutations, which have progressed following prior treatment with a new hormonal agent.
Results of the PROfound trial showed Lynparza significantly reduced the risk of disease progression or death by 66%, it added.
Prostate cancer is the second-most common cancer in men, with an estimated 1.3 million new cases diagnosed world-wide in 2018 and it is associated with a significant mortality rate, AstraZeneca noted.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 20, 2020 02:31 ET (07:31 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
